Compare LOAN & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOAN | LPCN |
|---|---|---|
| Founded | 1989 | 1997 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.9M | 61.8M |
| IPO Year | N/A | N/A |
| Metric | LOAN | LPCN |
|---|---|---|
| Price | $4.38 | $9.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 24.0K | ★ 83.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 9.96% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.47 | N/A |
| P/E Ratio | $9.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.29 | $2.52 |
| 52 Week High | $6.05 | $12.37 |
| Indicator | LOAN | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | 33.29 | 60.73 |
| Support Level | $4.48 | $8.35 |
| Resistance Level | $4.58 | $9.15 |
| Average True Range (ATR) | 0.07 | 0.74 |
| MACD | -0.00 | -0.15 |
| Stochastic Oscillator | 19.32 | 80.72 |
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.